Privia Health Group, Inc. (PRVA) AI Stock Analysis

Privia Health Group, Inc. functions as a national physician-enablement company operating across the United States. Founded in 2007 and headquartered in Arlington, Virginia, the company collaborates with medical groups, health plans, and health systems to optimize physician practices and elevate patient care across in-person and virtual settings. It provides technology solutions and population health tools designed to streamline clinical workflows for independent providers. In addition, Privia operates a management services organization (MSO) to reduce administrative burdens, a single-TIN medical group to align payer negotiations and clinical integration, and an accountable care organization (ACO) to enhance value-based care delivery.

Privia grew annual revenue from $966.2M in FY2021 to $2.12B in FY2025, achieving a 5-year revenue CAGR of 21.0%. Annual top-line growth rebounded to 22.3% in FY2025 following 4.7% growth in FY2024. Profitability improved from a net loss of -$188.2M in FY2021 to positive net income of $22.9M in FY2025, representing a net margin of 1.1%. For the latest quarter ended June 30, 2026, revenue increased 21.4% year-over-year and quarterly earnings surged 250.0% year-over-year, lifting trailing twelve-month revenue to $2.36B with an operating margin of 1.9%.

As of June 30, 2026, Privia held $412.20B in cash and short-term investments against $8.73B in total debt, leaving net cash of $403.47B. The balance sheet carried a current ratio of 1.62 and a debt-to-equity ratio of 0.01 against $782.33B in shareholders' equity. In FY2025, operating cash flow reached $163.4M and free cash flow was $162.2M, with capital expenditures of $1.2M. Over five years, the company's share count increased 23.2%.

Trading at $22.52 on October 16, 2026, Privia carries a market capitalization of $2.88B and an enterprise value of $2.04B. Its trailing P/E multiple of 107.2x sits well above the 24.6x median of its US-listed Healthcare peers, though its forward P/E of 17.3x equals the peer median of 17.3x. The stock trades at a price-to-sales multiple of 1.2x versus the peer median of 4.1x, and an EV/EBITDA of 35.8x versus the peer median of 12.0x. Over the past year, PRVA fell 11.8%, underperforming the 16.8% return of the S&P 500.

Wall Street coverage consists of 12 Strong Buy, 5 Buy, and 1 Hold ratings, with zero Sell ratings. The average price target is $31.47, indicating a 39.7% premium over the last close of $22.52. For the fiscal year ending December 31, 2026, consensus estimates project an EPS decline of 10.4% to $0.89 on revenue of $2.46B. For FY2027, 10 analysts anticipate EPS to grow 19.8% to $1.06 on revenue of $2.70B. Privia beat EPS estimates in 2 of the last 4 quarters, with its next earnings report set for November 5, 2026.

This page is an AI-written research summary of Privia Health Group, Inc. (PRVA). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: PRVA income statement, PRVA balance sheet, PRVA key metrics, PRVA analyst forecast, PRVA chart. See the PRVA stock overview for the latest quote and news.